首页 > 技术支持 > 文献速递

A glycan-based adjuvant expands the breadth and duration of protection of mRNA-based vaccines

Nature Immunology

The activation of pattern recognition receptors (PRRs) orchestrates inflammation and regulates adaptive immunity. To test whether tuning inflammation through PRR stimulation enhanced the efficacy of mRNA vaccines, we combined an mRNA-based vaccine generated against the ancestral spike protein of SARS-CoV-2 with mannadjuvant, a formulation of fungal mannan and aluminum hydroxide targeting the PRR dectin-2. In mice and non-human primates, mannadjuvant increased the magnitude and durability of the response elicited by the mRNA-based vaccine, and it also led to the induction of neutralizing antibodies directed against variants of concern with a high escape capacity, overcoming antigenic imprinting. Mechanistically, prolonged type I interferon (IFN) production and potentiated interleukin-1 (IL-1) signaling locally within the draining lymph node in mice or in human cells were necessary and sufficient to exert the effect of mannadjuvant. Our data indicate that antifungal PRRs can be harnessed to create more potent and durable mRNA-based vaccines.

https://doi.org/10.1038/s41590-026-02517-3

Related products

Catalog No. Product Name Description Target
VK565316 Anti-SARS-CoV-2 Spike Protein/RBD Broad-Neutralizing Reference Antibody (DH1047 Anti-SARS-CoV-2 Spike Protein/RBD Broad-Neutralizing Antibody (DH1047) (VK565316) is a research-grade recombinant antibody targeting Spike glycoprotein. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns. Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2